TB-500

A federal health advisory panel narrowly recommended easing FDA restrictions on peptides like BPC-157 and TB-500, despite objections from FDA scientists citing insufficient safety and efficacy data. The decision, with an 8-6 vote, could boost telehealth marketing of these substances for wellness uses, though the FDA is not obligated to follow the panel's advice.

An FDA advisory panel recommended allowing compounding pharmacies to produce peptides like BPC-157 and TB-500, despite FDA staff concerns about safety and efficacy. Sanofi's long-acting insulin pen, Lantus Solostar, faces supply shortages due to increased demand, causing challenges for diabetes patients.

The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend four unproven peptides (BPC-157, KPV, TB-500, and MOTS-c) for access through compounding pharmacies, despite scientific concerns.

An FDA advisory panel led by Robert F. Kennedy Jr. is reviewing seven banned therapeutic peptides, including BPC-157, TB-500, and epitalon, amid concerns over safety and efficacy. The two-day meeting (July 23-24) includes panelists with ties to peptide research, sales, or prescription, marking an unconventional approach to regulatory evaluation.

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to add peptides like BPC-157, KPV, TB-500, and MOTS-c to the list of substances compounding pharmacies can make, despite opposition from FDA scientists over concerns about their unproven benefits.

A US federal health advisory panel recommended easing restrictions on peptides like BPC-157, TB-500, and KPV, despite warnings from government scientists about their safety and effectiveness. The panel includes members linked to the peptides industry, and the decision may influence RFK Jr.'s stance.

A US health panel recommended easing restrictions on peptides like BPC-157, TB-500, and KPV, despite government scientists' warnings about their safety and effectiveness. The panel includes members linked to the peptides industry, and the decision may influence RFK Jr.

An FDA panel narrowly voted 8-6 to allow compounding pharmacies to produce BPC-157, a popular unapproved peptide promoted by influencers like Joe Rogan. The decision followed criticism from FDA scientists about the lack of evidence for its medical efficacy, while panel members included individuals with industry ties. Health Secretary Robert F. Kennedy Jr. supported the move, aiming to overturn Biden-era restrictions.

The FDA is evaluating whether seven peptides, including BPC-157 and TB-500, can be legally compounded, which may lead to increased availability in the U.S. The decision could determine the legal status of these peptides for broader use among Americans.

The FDA is reviewing seven unapproved peptides for potential inclusion in compounded prescription drugs, with meetings scheduled for July 23-24. These peptides, popular for weight loss, wound healing, and other health claims, are widely available through clinics and online sellers despite lacking FDA approval. HHS Secretary Robert F. Kennedy Jr. supports expanding access, while FDA reviewers express concerns about safety and efficacy.

The FDA is considering approval for compounding pharmacies to legally mix wellness peptides like BPC-157 and TB-500, which could create a $30 billion market. Telehealth companies like Hims & Hers, which previously profited from compounded Ozempic alternatives, are positioning to expand into peptide therapies despite limited long-term safety data.

The FDA's upcoming peptide safety review panel includes health professionals with financial ties to the peptide industry, a shift from previous academic-focused panels. The meeting, influenced by Health Secretary Robert F. Kennedy Jr.'s 'Make America Healthy Again' movement, will assess peptides like BPC-157 and TB-500, which the FDA has warned are unproven and risky.

The FDA will convene a panel to review the safety of popular peptide injections, with participants including doctors and pharmacists financially tied to the peptide industry. The meeting, part of efforts to reshape health policy under Robert F. Kennedy Jr., will assess peptides like BPC-157 and TB-500, which the FDA has previously warned are unapproved and risky.

The FDA's upcoming panel to review controversial peptide drugs includes health professionals with financial ties to the industry, including clinics and pharmacies promoting unproven peptides. The meeting follows concerns about the safety and regulatory status of substances like BPC-157 and TB-500, which are marketed for wellness purposes but lack scientific validation. Health Secretary Robert F. Kennedy Jr. has publicly supported these peptides.

The FDA plans to review easing restrictions on seven peptides, including BPC-157 and TB-500, amid pressure from Health Secretary Robert F. Kennedy Jr. and his allies. Critics warn that unregulated peptide use poses significant safety risks, as these substances lack clinical testing and FDA approval.